Trends in incidence of cutaneous malignant melanoma in Canada: 1992 Canada: -2010 Canada: versus 2011 Canada: -2015 To the Editor: The incidence of cutaneous malignant melanoma (CMM) worldwide continues to rise. 1 We recently reported a comprehensive, populationbased study of CMM in Canada during 1992-2010 and demonstrated a steady increase in its incidence across the Canadian provinces and territories, with a slight male predominance. Geographically, the highest CMM incidence rates were documented in the provinces of Nova Scotia and Prince Edward Island. 2 We extended this study and examined data on CMM incidence by using the Canadian Cancer Registry (2015 version) for the years 2011 to 2015 for all Canadian provinces except Quebec by using the International Classification of Diseases for Oncology, Third Edition, codes for all CMM subtypes, in a manner similar to that previously reported 2 ; we identified 27,095 patients (Table I) . Consistent with the previously reported trends, 2 this malignancy had a higher age-standardized incidence in males (23.2 cases per 100,000 in males per year vs 17.7 in females). The mean age of diagnosis was 64.9 6 14.7 years for males and 60.4 6 18.8 years for females (62.8 6 16.8 years for both sexes during 2011-2015 versus 58.5 6 21.6 during 1992-2010) (Table II) . Age range analysis confirmed these findings and showed that 60.3% of patients with CMM in Canada during the period from 2011 to 2015 were age 60 years or older (vs 48.7% in 1992-2010) (Table I) , with an overall increased percentage of the Canadian population older than 60 years in 2011-2015 (20.8% vs 17.4% in 1992-2010). This finding suggests that increasing age of the population contributes significantly to the increasing incidence of CMM.
Analysis of the anatomic location of CMM in 2011-2015 revealed trends similar to those in 1992-2010, where the majority (63%) of CMMs in males developed on the head and trunk, however, in females, the lower extremities were preferentially affected and accounted for 31.7% of cases (Table I) , further highlighting differences in sun exposure behaviors as possible contributing factors for these findings.
The age-standardized CMM incidence rate in Canada in 2011-2015 was 20.06 cases per 100,000 individuals per year (95% confidence interval, 19.82-20.30), as compared with the 1992-2010 rate of 12.27 (95% confidence interval, 12.18-12.36), demonstrating an ongoing steady increase. Agestandardized CMM incidence was highest in the province of Prince Edward Island, followed by Nova Scotia. The incidence rates for all provinces and territories are summarized in Table II . These findings highlight a consistent trend of increasing CMM incidence in Canada with the expected north-to-south gradient. Several factors may contribute to the high incidence of CMM in Prince Edward Island, including the province's aging population, proportion of individuals with Fitzpatrick type skin I to III, and relative abundance of water and sand (which are known to have increased surface reflection of ultraviolet radiation in comparison with that of grass). 3 Finally, analysis of CMM incidence by age group confirmed that the incidence increases with age, with important sex differences for each age category (Table I) .
The observed trends of increasing CMM incidence in the aforementioned preferential anatomic sites in men versus in women and differences in incidence rates across Canada further highlight the continuity of the aforementioned trends 2 and emphasize important sex-and age-specific differences in the incidence of melanoma. To decrease CMM incidence, stronger targeted public health efforts must be made. Specifically, we must strive to improve patient education in Canada and address sex-specific sun-seeking habits and exposures.
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Feras M. Ghazawi Abnormal erythrocyte morphology in drug reaction with eosinophilia and systemic symptoms
To the Editor: Drug rash with eosinophilia and systemic symptoms (DRESS) is a potentially fatal adverse drug reaction that is difficult to diagnose because of its wide range of clinical findings. Diagnosis is commonly made by using the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) scoring criteria, which include rash, fever, lymphadenopathy, eosinophilia, leukocyte abnormalities, thrombocytopenia, transaminitis, and other organ involvement. 1 Incidental abnormal erythrocyte morphology (AEM) is not in the existing diagnostic criteria, and to our knowledge, it has not been associated with DRESS in the literature. This study aimed to assess whether AEM is associated with DRESS.
A retrospective review of the charts of adult patients whose disease was diagnosed by the inpatient dermatology service at Wake Forest Baptist Medical Center and who experienced a drug eruption between January 2012 and July 2018 was performed. Demographics, RegiSCAR criteria, and presence or absence of AEM were noted. Patients with RegiSCAR scores of 2 or higher, indicating possible, probable, or definite cases of DRESS, were included in the DRESS cohort. 2 Patients in the control cohort were inpatients with a diagnosis of morbilliform drug eruption, Stevens Johnson syndrome, or toxic epidermal necrolysis. Only patients who had a complete blood count with differential performed at Wake Forest Baptist Medical Center were included. A Fisher exact test was performed to compare the prevalence of AEM between patients with DRESS and those with other drug eruptions.
The DRESS cohort included 38 patients. Their average age at diagnosis was 55 years. Fourteen patients were male. More than half (55%) of these patients had AEM (Table I ). The rates of other clinical findings associated with DRESS are displayed in Table II . Of the patients with DRESS who had AEM, 86% had eosinophilia and 67% had hepatic abnormalities. Of the patients with DRESS without AEM, 65% had eosinophilia and 41% had hepatic abnormalities. The cohort of patients with other drug eruptions included 246 patients; however, 31 were excluded because a complete blood count with differential was not performed during their hospitalization. Of the 215 patients included, 52 (24%) had AEM. AEM was more prevalent with DRESS than the other drug eruptions (P ¼ .0003). 
